GRAIL, Inc. Deferred Federal, State and Local, Tax Expense (Benefit)
GRAIL, Inc. (GRAL) reported Deferred Federal, State and Local, Tax Expense (Benefit) of -$127.28 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit · last filed 2026-03-12
- GRAIL, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2025 was -$127.28M.
- GRAIL, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2024 was -$133.73M.
- GRAIL, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2023 was -$38.15M.
- GRAIL, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2023 was -$39.06M.
| Period end | Deferred Federal, State and Local, Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$127.28M 10-K · filed 2026-03-12 |
| 2024-12-31 | -$133.73M 10-K · filed 2026-03-12 |
| 2023-12-31 | -$38.15M 10-K · filed 2025-03-05 |
| 2023-01-01 | -$39.06M 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |